Contact
Please use this form to send email to PR contact of this press release:
B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial
TO:
Please use this form to send email to PR contact of this press release:
B.More Receives FDA Investigational New Drug Approval for Psilocybin Alcohol Use Disorder Program Phase 2b Clinical Trial
TO: